Share results from the Phase 2 study of suzetrigine in lumbosacral radiculopathy
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Nov 2024
- Due
- 31 Dec 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Vertex continues to expect to share results from this study by the end of the year.”
What we found
Evidence strength A What the grades mean
The 10-K filed 2025-02-13 states that Vertex announced the Phase 2 suzetrigine LSR results in December 2024, within the year-end deadline.
-
A Vertex Pharmaceuticals 10-K filed 2025-02-13
“In December 2024, we announced Phase 2 clinical trial results showing that treatment with suzetrigine demonstrated a statistically significant and clinically meaningful within-group reduction in pain” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2025-02-13
“In December 2024, we announced results from a Phase 2 clinical trial evaluating suzetrigine in people with lumbosacral radiculopathy” ✓ confirmed on the page
Market reaction: the shares moved +0.6% against the S&P 500 over the three sessions around the disclosure (12 Feb 2025 to 18 Feb 2025). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Share
- Deliverable
- Suzetrigine Phase 2 lumbosacral radiculopathy study results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-VRTX-006544 · Corrections policy